Ankündigung • Jun 20
KKR Reportedly Eyes at Least $1 Billion Stake in Medicover's India Hospital Arm KKR & Co. Inc. (NYSE:KKR) is in advanced talks to buy a majority stake in the Indian business of Sweden’s Medicover AB (publ) (OM:MCOV B) for at least $1 billion, a source with direct knowledge of the matter said, a deal that would expand its healthcare bet in the world’s most populous nation. Stockholm-listed Medicover issued a press release soon after Reuters sent a request for comment on Wednesday night, saying Medicover Hospitals India (Medicover Healthcare Private Limited) is in discussions with KKR “regarding a potential sale of its Indian operations.”The company did not provide any details and Reuters is first to report that talks are ongoing for KKR to take a majority stake in the Indian business unit for at least $1 billion. Medicover, which entered the country in 2016, operates a network of 26 hospitals with around 6,000 beds. In its statement, it said it has also been preparing for an Indian initial public offering. Sweden’s Medicover owns 66.9 per cent of Medicover Hospitals India. KKR is seeking to acquire the Swedish firm’s entire stake for at least $1.05 billion and is also in discussions with minority shareholders. The “discussions are ongoing and a non-binding agreement has been reached,” said the person, who declined to be named publicly as the talks are private. Medicover did not respond to Reuters queries and KKR declined to comment. In its press release, Medicover said there is no certainty that discussions with KKR will result in any transaction and that the firm is continuing with the IPO process. KKR has been steadily increasing its healthcare investments in India. In 2024, the buyout firm bought a controlling stake in a hospital chain in the southern state of Kerala and has since backed the hospital group’s expansion through acquisitions. India’s hospital sector has attracted strong investor interest as rising incomes, expanding health insurance coverage and growing demand for quality healthcare drive consolidation and capacity expansion across the industry. Medicover competes with Apollo Hospitals, Aster Hospitals, and Fortis Healthcare in India. Rothschild is advising on the sale process, while Kotak is advising KKR, the person added. Kotak and Rothschild did not respond to Reuters queries. Ankündigung • Oct 23
Medicover Announces Additional Results from the Ongoing Dart Clinical Study from Oslo University Hospital Medicover announced additional results from the ongoing DART clinical study from Oslo University Hospital. The study utilises Medicover Genetics' hybrid capture-based, tumour-agnostic MRD assay. The additional results are based on an expanded population within the DART study and further strengthen the value of Medicover Genetics' ctDNA-based minimal residual disease (MRD) assay as a predictor of disease progression in patients with unresectable stage III non-small cell lung cancer (NSCLC). The results were presented through a poster presentation on 18 October 2025, at the European Society for Medical Oncology (ESMO) Congress in Berlin, where the study was recognised with one of the congress' Best Poster awards. The additional results represent another key milestone towards the clinical validation of Medicover Genetics' MRD assay and commercialisation. The mature data include 640 plasma samples from 84 patients. The study demonstrates that detectable circulating tumour DNA (ctDNA) during and after consolidative durvalumab following chemoradiotherapy (CRT) is strongly associated with inferior progression-free survival (PFS) and can predict disease progression months before radiological evidence. Data from the full 86-patient cohort will follow during the first half of 2026. Detection of ctDNA at six months after the initiation of durvalumab treatment was associated with inferior PFS (HR=2.45; 95% CI: 1.18-5.11; p=0.017). Likewise, detection of ctDNA three months after the end of durvalumab treatment were also associated with inferior PFS (HR=5.37; 95% CI: 1.,93-14.93; p=0.001). Importantly, ctDNA detection preceded imaging-based progression by a median of 7.4 months, demonstrating its potential as an early indicator of disease progression. The DART study (NCT04392505 /EudraCT 2019-002537-11) is a multicentre, prospective phase II trial including 86 patients with unresectable stage II NSCLC across several European centres. The study utilises Medic over Genetics' hybrid capture-based., tumour-agnostic MR DART assay, designed to detect and monitor minimal residual disease. Ankündigung • Oct 03
Medicover AB (publ), Annual General Meeting, Apr 29, 2026 Medicover AB (publ), Annual General Meeting, Apr 29, 2026. Ankündigung • Jun 19
Medicover AB (Publ) Announces Executive Changes Medicover AB (publ) announced Lukasz Krause will assume the role of CDIO as of 1 July 2025 and be part of the executive management team of Medicover. Lukasz brings a wealth of experience in IT management having successfully overseen the IT function for two-thirds of Medicover organisation as Head of IT for the Healthcare Services division over the past three years. He also brings extensive experience in managing IT in reputable international corporations prior to joining Medicover. Lukasz succeeds Jarek Urbanczyk, who is leaving the company after nearly 6 years of service. Ankündigung • Jun 03
Medicover Announces Positive Interim Results from the DART Clinical Study Medicover announced positive interim results from the DART clinical study conducted by Oslo University Hospital. The interim results indicate that by using Medicover Genetics' minimal residual disease (MRD) assay, MRD can be detected in patients with stage III non-small cell lung cancer (NSCLC) following chemoradiotherapy and durvalumab consolidation. In addition, it was found that detection of MRD during consolidative durvalumab was associated with inferior outcomes. The interim results were presented by Professor Aslaug Helland of Oslo University Hospital at the 2025 ASCO Annual Meeting. The interim results present a key milestone towards clinical validation of Medicover Genetics' MRD assay and commercialization. The DART study is a multicenter phase II clinical trial including 85 patients with unresectable stage III non-small cell Lung cancer (NSCLC) across multiple sites in Europe. All participants received chemoradiotherapy (CRT) followed by durvalumab consolidation therapy. Longitudinal plasma samples were collected at baseline (pre-CRT), at the initiation of durvalumab, and at predefined timepoints during durvalumab treatment and surveillance. The samples were analyzed using Medicover Genetics' novel, tumor-agnostic ctDNA-based MRD assay, which evaluates 293 genes and is tailored to each patient's individual biomarker profile using hybrid capture-based sequencing. The interim analysis included 20 patients who completed all scheduled blood draws, totaling 138 plasma samples. Key findings include: Detectable ctDNA in at least one plasma sample during the first four months after chemoradiotherapy was significantly associated with shorter progression-free survival (PFS) (HR: 4.7; 95% CI: 1.6-13.1; p = 0.004). Presence of ctDNA at four months post-CRT was also linked to shorter progression-free survival (HR: 3.77; 95% CI: 1.,32-10.74; p = 0.013). In contrast, ctDNA detection one month post-CRT was not significantly associated with reduced PFS (HR: 2.23; 95% CI: 0.78-6.36; p = 0.13). detection of ctDNA during the first four months post-CRT were associated with significantly increased odds of death within 24 months (OR: 16.48; 95% CI: 1; 1.29-1000.51; p = 0.017). These findings underscore the potential of ctDNA-basedMRD assessment as a prognostic biomarker to identify high-risk patients and guide more tailored interventions in this population. Ongoing Medicover work regarding the DART study is now focusing on completing the MRD testing for the entire patient cohort. Ankündigung • Apr 10
Medicover AB (publ) (OM:MCOV B) acquired Cityfit Sp Z O O in a transaction valued at approximately PLN 570 million. Medicover AB (publ) (OM:MCOV B) acquired Cityfit Sp Z O O in a transaction valued at approximately PLN 570 million on April 8, 2025. The transaction values CityFit at PLN 565 million (approximately €131 million) including assumed net debt with right-of-use liabilities and implies approximately a 7x LTM EBITDA multiple (excluding synergies). It will be EPS accretive from day one after completion. CityFit has generated the revenue for 2024 amounted to approximately €32 million (PLN 136.92 million). Following the acquisition, Medicover owns over 170 fitness clubs across Poland. CityFit’s staff will join the Medicover family.
Medicover AB (publ) (OM:MCOV B) completed the acquisition of Cityfit Sp Z O O on April 8, 2025. Ankündigung • Mar 22
Medicover AB (publ) Proposes Dividend for 2024, Payable on 9 May 2025 Medicover AB (publ) at its annual general meeting on 29 April 2025, board of directors proposed a dividend for 2024 of EUR 0.15 per share and 2 May 2025 as record date for dividend. Assuming this date will be the record date, Euroclear Sweden AB is expected to disburse dividends on 9 May 2025. The last day for trading in the company's share including the right to the dividend is 29 April 2025. Ankündigung • Feb 13
Medicover AB (Publ) Proposes Dividend for 2024 Medicover AB (publ) announced that its board of directors proposed a dividend for 2024 of €0.15 (€0.12) per share. Ankündigung • Feb 12
Medicover AB (Publ) Announces CEO Changes, Effective 1 May 2025 The Board of Directors of Medicover AB (publ) announced that John Stubbington will succeed Fredrik Rågmark as new CEO of the Medicover group from 1 May 2025. After 30 years with the Medicover group and 25 years as CEO, Fredrik Rågmark will step down from his operational role in Medicover by the end of April 2025 but will remain available to Medicover during 2025. John Stubbington, currently COO of Medicover'sHealthcare Services division, joined Medicover in 2010. Before joining Medicover, John held various positions within BUPA, the global health insurer, including nine years of working for their International division. Ankündigung • Oct 02
Medicover AB (publ) Announces Nomination Committee for the AGM 2025 Medicover AB (publ) publishes the nomination committee's composition for the annual general meeting in 2025. The nomination committee, which is appointed in accordance with the principles adopted by the annual general meeting on 26 April 2024, consists of: Fredrik Stenmo, representing Celox Holding AB and the Christina af Jochnick family's total shareholding; Hans Ramel, NG Invest Beta AB; Jannis Kitsakis, Fjärde AP-Fonden; Sophie Larsén, AMF och AMF Fonder. AGM to be held on 29 April 2025. Proposals should be submitted to the nomination committee no later than 11 March 2025. Ankündigung • Oct 01
Medicover AB (publ), Annual General Meeting, Apr 25, 2025 Medicover AB (publ), Annual General Meeting, Apr 25, 2025. Ankündigung • Aug 14
Medicover AB (publ) Appoints Anand Patel as Chief Financial Officer, Effective October 1, 2024 Medicover AB (publ) has signed a letter of intent with Anand Patel to join Medicover as the Chief Financial Officer (CFO) and member of the Executive Management Team. Anand will join Medicover from October 1, 2024, with the handover of the role during fourth quarter of 2024. Anand Patel has developed his career in the retail sector, where he has held international finance and business management positions and has extensive experience from Polish and Central- East Europe markets. He has served as the CFO and managing director of Pepco, a rapidly expanding international retail chain - one of the leading brands within the Pepco Group (publ). Pepco Group is listed on the Warsaw stock exchange since 2021 with a market cap of over EUR 2.4 billion. Before Pepco, Anand held the position of head of finance at other retail chains such as Halfords and Argos. Anand Patel will replace Joe Ryan, who has served as CFO of Medicover for over 28 years and will be retiring, as announced last year. Ankündigung • Jul 25
Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025 Medicover AB (publ) provided revenue guidance for year-end 2025. For the period, the company expects organic revenue should exceed €2.2 billion. Ankündigung • Apr 27
Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025 Medicover AB (publ) provided revenue guidance for year-end 2025. For the period, the company expects organic revenue should exceed €2.2 billion. Ankündigung • Jan 09
Medicover Appoints Kamila Skorupinski as Chief People Officer as of 1 April 2024 Medicover announced that Kamila Skorupinski will assume the role of Group Chief People Officer as of 1 April 2024 and be part of the executive management team. Kamila joined Medicover in January 2018, and since then, she has been HR Director for Healthcare Services. Ankündigung • Nov 05
Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025 Medicover AB (publ) provided revenue targets for by year-end 2025. For the period, the company announced Organic revenue should exceed €2.2 billion. Ankündigung • Nov 04
Medicover AB (Publ) Announces Resignation of Joe Ryan as Chief Financial Officer Joe Ryan, CFO, has announced that after 28 years with Medicover he will retire from the company during 2024. Joe Ryan will continue in the role until a successor is in place, ensuring continuity. A search process has started. Ankündigung • Sep 21
Medicover AB (publ) Announces Nomination Committee for the Annual General Meeting 2024 Medicover AB (publ) ("Medicover") publishes the nomination committee's composition for the annual general meeting in 2024. The nomination committee, which is appointed in accordance with the principles adopted by the annual general meeting on 27 April 2023, consists of: Fredrik Stenmo, representing Celox Holding AB and the Christina af Jochnick family's total shareholding, Hans Ramel, NG Invest Beta AB, Jannis Kitsakis, Fjärde AP-Fonden, Angelica Hanson, AMF och AMF Fonder. Ankündigung • Sep 20
Medicover AB (publ), Annual General Meeting, Apr 26, 2024 Medicover AB (publ), Annual General Meeting, Apr 26, 2024. Ankündigung • Feb 18
Medicover AB (publ) Proposes Dividend for 2022 Medicover AB (publ) board of directors proposed a dividend for 2022 of €0.12 (€0.12) per share. Ankündigung • Oct 22
Medicover AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023 Medicover AB (publ) announced that they will report fiscal year 2022 results on Feb 17, 2023